» Articles » PMID: 34079083

WNT5A Inhibition Alters the Malignant Peripheral Nerve Sheath Tumor Microenvironment and Enhances Tumor Growth

Overview
Journal Oncogene
Date 2021 Jun 3
PMID 34079083
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas that cause significant mortality in adults with neurofibromatosis type 1. We compared gene expression of growth factors in normal human nerves to MPNST and normal human Schwann cells to MPNST cell lines. We identified WNT5A as the most significantly upregulated ligand-coding gene and verified its protein expression in MPNST cell lines and tumors. In many contexts WNT5A acts as an oncogene. However, inhibiting WNT5A expression using shRNA did not alter MPNST cell proliferation, invasion, migration, or survival in vitro. Rather, shWNT5A-treated MPNST cells upregulated mRNAs associated with the remodeling of extracellular matrix and with immune cell communication. In addition, these cells secreted increased amounts of the proinflammatory cytokines CXCL1, CCL2, IL6, CXCL8, and ICAM1. Versus controls, shWNT5A-expressing MPNST cells formed larger tumors in vivo. Grafted tumors contained elevated macrophage/stromal cells, larger and more numerous blood vessels, and increased levels of Mmp9, Cxcl13, Lipocalin-1, and Ccl12. In some MPNST settings, these effects were mimicked by targeting the WNT5A receptor ROR2. These data suggest that the non-canonical Wnt ligand WNT5A inhibits MPNST tumor formation by modulating the MPNST microenvironment, so that blocking WNT5A accelerates tumor growth in vivo.

Citing Articles

Malignant peripheral nerve sheath tumor: models, biology, and translation.

Somatilaka B, Sadek A, McKay R, Le L Oncogene. 2022; 41(17):2405-2421.

PMID: 35393544 PMC: 9035132. DOI: 10.1038/s41388-022-02290-1.


WNT/β-Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?.

Martinez-Font E, Perez-Capo M, Vogler O, Martin-Broto J, Alemany R, Obrador-Hevia A Cancers (Basel). 2021; 13(21).

PMID: 34771683 PMC: 8583315. DOI: 10.3390/cancers13215521.

References
1.
Evans D, Howard E, Giblin C, Clancy T, Spencer H, Huson S . Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010; 152A(2):327-32. DOI: 10.1002/ajmg.a.33139. View

2.
Brosseau J, Liao C, Wang Y, Ramani V, Vandergriff T, Lee M . NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. Nat Commun. 2018; 9(1):5014. PMC: 6258697. DOI: 10.1038/s41467-018-07452-y. View

3.
Widemann B . Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep. 2009; 11(4):322-8. PMC: 6689400. DOI: 10.1007/s11912-009-0045-z. View

4.
Bos J, Rehmann H, Wittinghofer A . GEFs and GAPs: critical elements in the control of small G proteins. Cell. 2007; 129(5):865-77. DOI: 10.1016/j.cell.2007.05.018. View

5.
Simanshu D, Nissley D, McCormick F . RAS Proteins and Their Regulators in Human Disease. Cell. 2017; 170(1):17-33. PMC: 5555610. DOI: 10.1016/j.cell.2017.06.009. View